Gadolinium-enhanced coronary CT angiography: Improved safety?

Heart

Volumn 96, Issue 19, 2010, Pages 1513-1515

  Pugliese, Francesca ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID; IODINE;

ANGIOCARDIOGRAPHY; CHRONIC KIDNEY DISEASE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTRAST ENHANCEMENT; CONTRAST INDUCED NEPHROPATHY; DIAGNOSTIC IMAGING; DRUG SAFETY; EDITORIAL; GLOMERULUS FILTRATION RATE; HUMAN; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RISK FACTOR;

CONTRAST MEDIA; CORONARY ANGIOGRAPHY; GADOLINIUM; HUMANS; IODINE COMPOUNDS; KIDNEY DISEASES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77957302432     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2010.195180     Document Type: Editorial

References (15)

1. Carrascosa P, Capunay C, Deviggiano A, et al. Feasibility of 64-slice gadolinium enhanced computed tomography for the evaluation of obstructive coronary artery disease. Heart 2010;96:1543-9.
2. Budoff MJ, Lu B, Mao S. Gadolinium-enhanced three-dimensional electron beam coronary angiography. J Comput Assist Tomogr 2002;26:879. (Pubitemid 36076699)
3. Grobner T. Gadoliniumea specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21:1104-8.
4. DeHoratius DM, Cowper SE. Nephrogenic systemic fibrosis: an emerging threat among renal patients. Semin Dial 2006;19:191-4.
5. Thomsen HS. Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol 2006;16:2619-21.
6. Morcos SK. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br J Radiol 2007;80:73-6. Erratum. Br J Radiol 2007;80:586. (Pubitemid 47343090)
7. Frenzel T, Lengsfeld P, Schirmer H, et al. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol 2008;43:817-28.
8. McCullough PA, Adam A, Becker CR, et al. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol 2006;98:5K-13.
9. Ergun I, Keven K, Uruc I, et al. The safety of gadolinium in patients with stage 3 and 4 renal failure. Nephrol Dial Transplant 2006;21:697-700.
10. Haustein J, Niendorf HP, Krestin G, et al. Renal tolerance of gadolinium-DTPA/dimeglumine in patients with chronic renal failure. Invest Radiol 1992;27:153-6.
11. Thomsen HS, Almen T, Morcos SK. Gadolinium-containing contrast media for radiographic examinations: a position paper. Eur Radiol 2002;12:2600-5.
12. Nyman U, Elmstahl B, Leander P, et al. Are gadolinium-based contrast media really safer than iodinated media for digital subtraction angiography in patients with azotemia? Radiology 2002;223:311-18; discussion 28-9.
13. Cardinal HN, Holdsworth DW, Drangova M, et al. Experimental and theoretical x-ray imaging performance comparison of iodine and lanthanide contrast agents. Med Phys 1993;20:15-31. (Pubitemid 23069853)
14. Mortele KJ, Oliva MR, Ondategui S, et al. Universal use of nonionic iodinated contrast medium for CT: evaluation of safety in a large urban teaching hospital. AJR Am J Roentgenol 2005;184:31-4.
15. Abujudeh HH, Kosaraju VK, Kaewlai R. Acute adverse reactions to gadopentetate dimeglumine and gadobenate dimeglumine: experience with 32,659 injections. AJR Am J Roentgenol 2010;194:430-4.